Embed Size (px)
Citation preview
Medicines Transparency Alliance21/04/23
Updates on Quality Presentations et al.
John AlloteyManager, Business DevelopmentsLaGray Chemical Company LimitedNsawam, Ghana
Medicines Transparency Alliance
Key Issues
Quality issues are very complex issues
Quality vital in access to medicines
Unavailability of appropriate data
– Decisions made based on inadequate information or influences of donors
Existence of counterfeit and sub-standard medicines
Capacity to ensure good quality medicines
21/04/23
Medicines Transparency Alliance
Successes
Successful completion of studies leading to necessary regulatory outcomes
– Data for Change in legislation
– Mapping of pharmacies in Bishkek
Regulatory Interventions undertaken to address problems
– Withdrawal of products
– Re-analysis of retained samples
– Communication to providers and public
– Withdrawal of all unregistered products
– Intensified Post market surveillance
21/04/23
Medicines Transparency Alliance
Challenges
Communication with different players, red tape-ism
Legislation gaps
Regulation and post market surveillance weakness
Awareness creation for prescribers, dispensers and patients
The future of the mini labs???
Sensitivities surrounding quality
– Good communication
– Engagement of relevant stakeholders
Education of consumers on the existence of good quality generics
21/04/23
Medicines Transparency Alliance
Lessons Learned
Increased enforcement of regulatory requirements is essential to ensure medicines are of right quality
The minilab technique has tremendous impact on quality testing of medicines
MeTA should seek ways of facilitating support in capacity building for local manufacturers
Need to strengthen the Post-market surveillance activities of national regulators
Every little support helps and MeTA support has been highly beneficial
21/04/23
Medicines Transparency Alliance
In Conclusion
Develop policy solutions that reduce risks due to low quality drugs and increase confidence in the system (acceptance of generic drugs!)
Complete PARADIGM SHIFT required to shift focus from “big pharma” to availability of quality generics??
MeTA as a multi-stakeholder group is key in achieving
Need to secure support to prosecute this agenda!
21/04/23
Medicines Transparency Alliance
Thank you
John Allotey
Email: [email protected]
Skype: johnnie_allotey
Mobile number: +233-20-831-7767
Website: www.lagraychem.com
21/04/23
